Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) is now available.
Recordati has published its half-year financial report as of June 30, 2025, which has been approved by the Board of Directors and is now accessible to the public. This announcement underscores Recordati’s commitment to transparency and its strategic positioning in the pharmaceutical industry, potentially impacting stakeholders by providing insights into the company’s financial health and operational progress.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. is an international pharmaceutical group with Italian origins, offering therapeutic options in specialty and general medicine, as well as rare diseases. The company is listed on the Italian Stock Exchange and operates in about 150 countries across the EMEA, Americas, and APAC regions, employing over 4,450 people.
Average Trading Volume: 289,011
Technical Sentiment Signal: Buy
Current Market Cap: €11.21B
See more insights into REC stock on TipRanks’ Stock Analysis page.